Cellular uptake of S413-PV peptide occurs upon conformational changes induced by peptide–membrane interactions  by Mano, Miguel et al.
1758 (2006) 336–346
http://www.elsevier.com/locate/bbaBiochimica et Biophysica ActaCellular uptake of S413-PV peptide occurs upon conformational changes
induced by peptide–membrane interactions
Miguel Mano a,b, Ana Henriques c, Artur Paiva c, Manuel Prieto d, Francisco Gavilanes e,
Sérgio Simões a,f, Maria C. Pedroso de Lima a,b,⁎
a Centro de Neurociências e Biologia Celular, Universidade de Coimbra, Portugal
b Departamento de Bioquímica, Faculdade de Ciências e Tecnologia, Universidade de Coimbra, Portugal
c Centro de Histocompatibilidade de Coimbra, Portugal
d Centro de Química-Física Molecular, Instituto Superior Técnico, Lisboa, Portugal
e Departamento de Bioquímica y Biologia Molecular I, Facultad de Ciencias Químicas, Universidad Complutense de Madrid, Spain
f Laboratório de Tecnologia Farmacêutica, Faculdade de Farmácia, Universidade de Coimbra, Portugal
Received 29 September 2005; received in revised form 16 January 2006; accepted 18 January 2006
Available online 10 February 2006Abstract
In face of accumulated reports demonstrating that uptake of some cell-penetrating peptides occurs through previously described endocytic
pathways, or is a consequence of cell fixation artifacts, we conducted a systematic analysis on the mechanism responsible for the cellular uptake of
the S413-PV karyophilic cell-penetrating peptide. The results reviewed here show that the S413-PV peptide is able to very efficiently accumulate
inside live cells in a rapid, non-toxic and dose-dependent manner, through a mechanism distinct from endocytosis. Comparative analysis of
peptide uptake by mutant cells lacking heparan sulfate proteoglycans demonstrates that, although not mandatory, their presence at cell surface
facilitates the cellular uptake of the S413-PV peptide. Furthermore, we demonstrate that upon interaction with lipid vesicles, the S413-PV peptide
undergoes significant conformational changes that are consistent with the formation of helical structures. Such conformational changes occur
concomitantly with a penetration of the peptide into the lipid bilayer, strongly suggesting that the resulting helical structures are crucial for the
non-endocytic cellular uptake of the S413-PV peptide. Overall, our data support that, rather than endocytosis, the cellular uptake of the S413-PV
cell-penetrating peptide is a consequence of its direct translocation through cell membranes following conformational changes induced by
peptide–membrane interactions.
© 2006 Elsevier B.V. All rights reserved.Keywords: Cell-penetrating peptide; Protein transduction domain; Peptide–membrane interaction; Tryptophan fluorescence; Circular dichroism; Amphipathic
alpha-helix1. Introduction
Cell-penetrating peptides (CPPs) have been shown to very
efficiently cross eukaryotic cell membranes through a temper-
ature-insensitive and energy-independent mechanism that doesAbbreviations: CPP, cell-penetrating peptide; GAG, glycosaminoglycan;
HSPG, heparan sulfate proteoglycan; LUV, large unilamellar vesicle; POPC, 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; POPG, 1-palmitoyl-2-oleoyl-
sn-glycero-3-[phospho-rac-(1-glycerol)]; CD, circular dichroism
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doi:10.1016/j.bbamem.2006.01.014not involve membrane receptors or transporters. Interestingly,
cell-penetrating peptides also have the remarkable ability to
mediate the intracellular delivery of a wide variety of molecules
of pharmacological interest, both in vitro and in vivo (for recent
reviews, see [1–5]).
Despite great variability in the amino acid sequence, CPPs
are usually short peptide sequences rich in basic amino acids,
in some cases exhibiting the ability to be arranged in
amphipathic alpha-helices. The peptides derived from the
HIV-1 Tat protein and from the homeodomain of the
Antennapedia protein of Drosophila (Tat and Penetratin
(pAntp) peptides, respectively) [6,7], as well as the synthetic
Pep-1 peptide [8] are among the best-characterized cell-
penetrating peptides.
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to enter into a wide variety of cell types from different tissues
and organisms, the glycosaminoglycan (GAG) moieties of the
ubiquitous cell surface heparan sulfate proteoglycans (HSPGs)
have been identified as playing an important role in mediating
electrostatic interactions of cell-penetrating peptides with
biological membranes [9,10].
Despite the widespread use of cell-penetrating peptides for
delivery purposes and the extensive research on the unusual
ability of these peptides to traverse cell membranes and promote
intracellular uptake of various cargo molecules, the mechanisms
underlying the cellular uptake of CPPs are not completely
elucidated. Recent reports attributing the cellular uptake and
nuclear accumulation of some cell-penetrating peptides to an
artifactual redistribution of membrane-associated peptide mole-
cules and conjugates [11–13], have motivated a re-evaluation of
the mechanisms responsible for their cellular uptake. Interest-
ingly, results from criterious re-evaluations of cellular uptake
under experimental conditions that avoid artifactual observa-
tions, have implicated the involvement of well-characterized
endocytic pathways, such as clathrin-mediated endocytosis
[10], caveolae-mediated endocytosis [14,15] or macropinocy-
tosis [16,17] in the internalization of several peptides and their
conjugates.
Given the conflicting results regarding the mechanisms on
the cellular uptake of cell-penetrating peptides, we have
previously characterized the cellular uptake of the S413-PV
karyophilic cell-penetrating peptide [18]. In the present
manuscript, we review research results obtained in our
laboratory on the interaction of S413-PV peptide with cells
and model membranes, aimed to understand the sequence of
events underlying translocation of this peptide across biological
membranes. The S413-PV cell-penetrating peptide results from
the combination of a 13 amino acid cell-penetrating sequence,
derived from the Dermaseptin S4 peptide, with the SV40 large
T antigen nuclear localization signal [19]. Table 1 compares the
amino acid sequence of the S413-PV peptide with those of cell-
penetrating peptides commonly used for cargo delivery.
Collectively, the obtained data indicate that the cellular
uptake of the S413-PV peptide is a very efficient, non-toxic and
dose-dependent process, which occurs mainly through a
mechanism distinct from endocytosis, most likely involving
the direct penetration of the peptide through cell membranes.Table 1
Comparison of the sequences of the S413-PV, reverse NLS and scrambled









SV40 large T antigen nuclear localization signal is underlined in the sequence of
Pep-1, S413-PV and reverse NLS peptides; in the reverse NLS peptide, the
sequence corresponding to the NLS of SV40 (aa 14–20) is inverted.Comparative analysis of peptide uptake by mutant cells lacking
heparan sulfate proteoglycans, as well as studies with model
membranes, demonstrate that the presence of HSPGs or other
negatively charged components on the surface of target
membranes potentiates the extent of peptide–membrane inter-
actions, which are mainly of electrostatic nature. As a
consequence of these peptide–membrane interactions, the
S413-PV peptide becomes inserted into the lipid bilayer,
which occurs concomitantly with significant conformational
changes of the peptide that are consistent with an increase in its
helical content. Comparative analysis using different peptides
demonstrates that these conformational changes are dependent
on the peptide sequence, providing clear evidence that the
secondary structure acquired by the S413-PV peptide upon its
interaction with target membranes is intricately related to its
capacity to translocate across cell membranes.
2. Materials and methods
2.1. Cells
HeLa cells (human epithelial cervical carcinoma) were maintained at 37 °C,
under 5% CO2, in Dulbecco Modified Eagle medium-high glucose (DMEM;
Sigma, St. Louis, MO) supplemented with 10% (v/v) heat-inactivated fetal
bovine serum (Biochrom KG, Berlin, Germany), and with 100 units penicillin
and 100 μg streptomycin (Sigma) per ml.
CHO-K1 and pgs A-745 Chinese hamster ovary cell lines were grown in F-
12 (Ham) Nutrient Mixture (Invitrogen, UK) supplemented with 10% fetal
bovine serum, penicillin (100 units/ml) and streptomycin (100 μg/ml), 2 mM L-
glutamine (Sigma), 10 mM HEPES (Sigma) and 14 mM sodium bicarbonate
(Sigma).
2.2. Peptides
High purity (N95%) S413-PV peptide (ALWKTLLKKVLKAPKKKRKVC),
reverse NLS peptide (ALWKTLLKKVLKAVKRKKKPC) and scrambled
peptide (KTLKVAKWLKKAKPLRKLVKC) were obtained from Thermo
Electron (Thermo Electron GmbH, Germany). In the reverse NLS peptide, the
sequence corresponding to the nuclear localization signal of the SV40 large T
antigen (aa 14–20) is inverted; the scrambled peptide was generated based on
the S413-PV peptide sequence, so that the resulting peptide had the same amino
acid composition and overall charge, but a distinct primary sequence. During
synthesis, peptides were either fluorescently labeled with 5-(6)-tetramethylrho-
damine (TAMRA), or modified with an acetyl group at the N-terminus, and
further modified by introducing an amide group at the C-terminus. Freeze-dried
peptides were reconstituted in high purity water.
Peptide concentration was determined by amino acid analysis and light
absorption at 280 nm. Amino acid analysis was performed in a Beckman 6300
automatic analyzer, following acid hydrolysis of the peptide.
2.3. Peptide cellular uptake
For experiments on peptide uptake, 0.8×105 cells/well were seeded onto 12-
well plates (flow cytometry) or 12-well plates containing 16 mm glass coverslips
(confocal microscopy), 24 h prior to incubation with the peptide. The cells were
then washed with phosphate-buffered saline (PBS) and incubated with 1.0 μM
of either the S413-PV peptide or scrambled peptide, in serum-free medium, for
30 min or 1 h, at 37 °C.
Analysis of peptide internalization was performed by confocal laser
scanning microscopy and flow cytometry. To avoid any possible artifactual
observations caused by cell fixation, analysis of peptide uptake was performed
always in live cells.
To address the effect of drugs that compromise different endocytic pathways
on the uptake of the S413-PV peptide, HeLa cells were washed with PBS and
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30 μM chlorpromazine (CHP; Sigma); (ii) 5 mM methyl-β-cyclodextrin
(MβCD; Sigma); (iii) 25 μg/ml nystatin (Sigma); (iv) 5 μM cytochalasin D
(Sigma); (v) 5 mM amiloride (Sigma). The cells were then incubated with the
peptide in the presence of each drug, for 1 h, at 37 °C, in serum-free DMEM.
The effect of heparin on the cellular uptake of the S413-PV peptide was also
evaluated. For this purpose, HeLa cells were washed with PBS and then pre-
treated for 30 min, at 37 °C, in serum-free DMEM, with 10 μg/ml heparin
(sodium salt from bovine intestinal mucosa; Sigma), followed by incubation
with the peptide in the presence of heparin, for 1 h, at 37 °C, in serum-free
DMEM. The concentration of heparin used in this study corresponds to a clear
excess of negative charges with respect to the positive charges of the peptide,
which allows to accurately mimic the interaction of the peptide with a cell
surface rich in heparan sulfate proteoglycans.
The effect of the drugs that affect different endocytic pathways was
confirmed, in parallel control experiments, by analyzing the cellular uptake of
fluorescently labeled transferrin, a known marker of clathrin-mediated
endocytosis, and lactosylceramide, a marker of raft/caveolae-dependent
endocytosis (data not shown). No significant cytotoxicity was associated to
the treatment of cells with any of the drugs used in this study (data not
shown).
Flow cytometry analysis was performed in live cells, using a Becton
Dickinson FACSCalibur flow cytometer. Data were obtained and analyzed using
CellQuest software (BD Biosciences). Since flow cytometry analysis does not
discriminate between membrane-associated and internalized peptide, after
incubation with the different peptides, the cells were washed once with PBS and
trypsinized (10 min, 37 °C) to remove any surface-bound, non-internalized
peptide, which could result in an overestimation of cellular uptake. The cells
were then further washed, resuspended in PBS, and immediately analyzed. Live
cells were gated by forward/side scattering from a total of 10000 events.
For analysis of the subcellular localization of the peptides by confocal
microscopy, following peptide–cell incubation the cells were washed and
mounted in PBS, and immediately visualized. Observations were performed, in
live cells, using a Bio-Rad MRC 600 fluorescence confocal microscope
equipped with an argon/krypton laser (Bio-Rad Laboratories, Inc.).
2.4. Liposome preparation
Large unilamellar vesicles (LUVs) were prepared by extrusion of multi-
lamellar vesicles composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocho-
line (POPC; Avanti Polar Lipids, AL), 1-palmitoyl-2-oleoyl-sn-glycero-3-
[phospho-rac-(1-glycerol)] (POPG; Avanti), or mixtures of these two lipids at
different molar ratios [(POPC:POPG (1:1) and POPC:POPG (4:1)].
Lipid solutions in chloroform were mixed at the desired molar ratios, and
dried under vacuum, at room temperature, using a rotary evaporator. The dried
lipid films were then hydrated with 1.0 ml high purity water, and the
multilamellar vesicles obtained were briefly sonicated and extruded 21 times
through two stacked polycarbonate filters (100 nm pore diameter) using a
Liposofast device (Avestin, Toronto, Canada).
Total lipid concentrations of the resulting LUVs were determined by the
Bartlett method [20], and 10 mM stock solutions of the different liposome
formulations were prepared.
2.5. Steady-state fluorescence spectroscopy
Steady-state fluorescence measurements were performed in a SPEX
Fluorolog 2 spectrofluorometer, at room temperature, using 10×2 mm, or
5×5 mm quartz cuvettes.
Interaction of S413-PV peptide with lipid vesicles of different compositions
(LUVs) was assessed by following peptide intrinsic fluorescence upon sequential
addition of small volumes of concentrated vesicle stock solutions to peptide
samples, up to a lipid/peptide molar ratio of 40. Experiments were performed in
10 mM sodium phosphate buffer (pH 7.0), and concentration of S413-PV peptide
was 2.5 μM. Excitation wavelength was 280 nm and fluorescence emission was
scanned from 300 to 400 nm.
All spectra were corrected for background contributions of buffer, and of
different concentrations of vesicles. Spectra were not corrected for the
photomultiplier wavelength dependence.2.6. Partition coefficients
Partition coefficients (Kp) were determined based on the changes in the
fluorescence intensity of the S413-PV peptide observed in the presence of lipid
vesicles of different compositions. The relationships and assumptions used to
determine Kp were previously described [21],
I ¼ IW þ ILKpV¯ L½L
1þ KpV¯ L½L ð1Þ
where I is the fluorescence intensity for each lipid concentration [L], and Ii the
values in phase i (I=W, L). A nonlinear fit of Eq. (1) to the data yields the values
of IL and Kp. The lipid molar volume V¯L=0.637 dm
3 M−1 used in this work is
obtained from extrapolation from available data in the literature [22].
2.7. Quenching of tryptophan fluorescence
Quenching of tryptophan fluorescence by acrylamide was evaluated either in
aqueous buffer, or in the presence of lipid vesicles, at the lipid/peptide molar
ratio of 40. Under the different experimental conditions, the quenching constants




¼ 1þ KSV Q½  ð2Þ
where F0 and F are the fluorescence intensities of tryptophan emission in the
absence and presence of the quencher, respectively, and [Q] is the molar
concentration of the quencher in the sample.
Emission spectra of the S413-PV peptide (2.5 μM) were acquired as
described previously, in the presence of different acrylamide concentrations (5–
100 mM). Acrylamide was added from a 1.0 M aqueous stock solution. Spectra
were corrected for background fluorescence of buffer, vesicles and different
concentrations of acrylamide, as well as for the inner filter effect.
2.8. Circular dichroism spectroscopy
Circular dichroism (CD) spectra were acquired in a Jasco J-715 spectro-
polarimeter using 1.0 mm quartz cuvettes. Experiments were performed at
15 °C, in 10 mM sodium phosphate buffer (pH 7.0), or in the same buffer
containing lipid vesicles, at different lipid/peptide molar ratios. Five spectra
were collected and averaged for each sample. Peptide concentrations ranged
from 5 to 50 μM, and maximal lipid concentration was 0.2 mM. All spectra were
corrected for background contributions of buffers and lipid vesicles, and
smoothed using the Jasco J-715 noise reduction software.
To facilitate interpretation of the circular dichroism spectra obtained under
the different experimental conditions, the relative contribution of three
secondary structure elements (α-helix, β-structure and random coil) to the
overall structure of the peptide was estimated by computer fitting of the CD
spectra according to the algorithm convex constraint analysis (CCA).
3. Results
3.1. Cellular uptake of S413-PV cell-penetrating peptide
To evaluate the efficiency of S413-PV peptide internalization,
flow cytometry analysis of HeLa cells exposed to increasing
concentrations of rhodamine-labeled peptide was performed.
Enzymatic digestion of membrane-associated, non-internalized
peptide prior to flow cytometry analysis ensured an accurate
evaluation of peptide uptake.
Analysis of the flow cytometry results revealed that the
number of cells containing the peptide and the amount of
peptide internalized by cells markedly increased with
peptide concentration, within the concentration range
examined (Fig. 1a).
Fig. 1. Cellular uptake of S413-PV cell-penetrating peptide. (a) Effect of the S413-PV peptide dose on its cellular uptake. HeLa cells were incubated with increasing
concentrations of rhodamine-labeled S413-PV peptide, at 37 °C, for 1 h. Extent of peptide uptake was analyzed by flow cytometry following cell treatment with trypsin,
to remove non-internalized, surface-bound peptide. (b) Effect of peptide sequence on peptide uptake. HeLa cells were incubated with 1.0 μM of rhodamine-labeled
S413-PV or scrambled peptides, at 37 °C, for 30 min. Cells were washed and immediately observed by confocal fluorescence microscopy. All experiments were
performed using live cells.
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peptide have similar physico-chemical properties (peptide
length, mass and charge), the extent of cellular uptake of the
S413-PV peptide was significantly higher than that observed for
the scrambled peptide (Fig. 1b). Additionally, the two peptides
presented clearly distinct subcellular localizations: the S413-PV
peptide was distributed throughout the cytoplasm and nucleus
of cells, accumulating in nucleoli, whereas the scrambled
peptide presented a punctate cytoplasmic distribution, which is
consistent with its uptake through an endocytic mechanism
(Fig. 1b).
Additional studies aimed at evaluating the effect of the
peptides on membrane integrity revealed that incubation of
HeLa cells with the S413-PVor scrambled peptides up to 2.0 μM
concentration does not result in significant cytotoxicity, as
assessed by propidium iodide exclusion by viable cells ([18]
and data not shown).The different cellular uptake of the S413-PV and scrambled
peptides highlights the relevance of peptide sequence in
dictating the mechanism and efficiency of peptide uptake,
which ultimately determine its intracellular fate.
3.2. Mechanisms of peptide cellular uptake
In face of recent reports demonstrating that endocytosis is
responsible for the cellular uptake of several cell-penetrating
peptides, the involvement of endocytosis in the cellular uptake
of the S413-PV peptide was carefully evaluated.
Endocytosis is a very complex cellular process that may
occur through several distinct mechanisms, usually divided into
two broad categories: phagocytosis, a process restricted to
specialized mammalian cells, and pinocytosis, which occurs in
all mammalian cells and encompasses macropinocytosis,
clathrin-mediated endocytosis, caveolae-mediated endocytosis,
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independent endocytic pathways [25,26].
To investigate the involvement of the different endocytic
pathways in the cellular uptake of the S413-PV peptide, the
effect of chlorpromazine (a known inhibitor of clathrin-
mediated endocytosis), of MβCD and nystatin (which deplete
or sequester membrane cholesterol, inhibiting endocytic path-
ways dependent on lipid-rafts such as macropinocytosis,
caveolae- and clathrin-mediated endocytosis [26]), of cytocha-
lasin D (an inhibitor of F-actin elongation required for
phagocytosis, macropinocytosis and caveolar endocytosis
[27]) and of amiloride (which specifically blocks the Na+/H+
exchange required for macropinocytosis [28]), was evaluated.
As can be observed in Fig. 2, only cytochalasin D had a
significant inhibitory effect on the extent of cellular uptake of
the S413-PV peptide, which might support a role for endocytosis
in the internalization of this peptide. However, the lack of
inhibition observed for all the other tested drugs, which also
compromise the endocytic pathways that are affected by
cytochalasin D, consistently excluded the involvement of
endocytosis in the cellular uptake of the S413-PV peptide, at a
peptide concentration that results in its efficient cellular uptake
by the majority of cells (1.0 μM).
3.3. Role of heparan sulfate proteoglycans (HSPGs) in peptide
uptake
As a first approach to address the involvement of cell surface
heparan sulfate proteoglycans in the cellular uptake of the S413-Fig. 2. Effect of different drugs on the cellular uptake of S413-PV peptide. Flow
cytometry quantification of the extent of cellular uptake of S413-PV peptide in
the presence of drugs that inhibit different endocytic pathways, or heparin. HeLa
cells pre-treated with the different drugs for 30 min, at 37 °C, were incubated, in
the presence of the drugs, with fluorescently-labeled S413-PV peptide (1.0 μM,
1 h), at the same temperature, as described in Materials and methods. Flow
cytometry analysis was performed in live cells, following treatment with
trypsin, to remove non-internalized, surface-bound peptide. Chlorpromazine
(CHP) inhibits clathrin-mediated endocytosis, MβCD and nystatin inhibit
endocytic pathways dependent on lipid-rafts by depleting or sequestering
membrane cholesterol, cytochalasin D (cytD) inhibits F-actin elongation
required for phagocytosis, macropinocytosis, caveolar endocytosis, as well as
other cellular processes, and amiloride blocks the Na+/H+ exchange required for
macropinocytosis. Heparin mimics glycosaminoglycan moieties of cell surface
heparan sulphate proteoglycans.PV peptide, the competitive effect of heparin on this process
was evaluated. Heparin mimics the glycosaminoglycan moieties
of proteoglycans ubiquitously present at cell surfaces, and has
been shown to bind Tat peptide very efficiently [29] and to
impair the cellular uptake of Tat fusion proteins [9,15,17,30].
Results from these experiments demonstrated that heparin
completely blocks the cellular uptake of the S413-PV peptide
(Fig. 2), strongly suggesting that cell surface proteoglycans play
an important role in peptide–cell interaction.
To accurately evaluate the relevance of cell surface heparan
sulfate proteoglycans to the interaction of the S413-PV peptide
with biological membranes, comparative uptake studies were
performed in CHO-K1 and pgs A-745 cell lines. pgs A-745 is a
mutant cell line derived from CHO-K1 that is unable to
synthesize proteoglycans, since it is defective in xylosyltrans-
ferase I, an enzyme involved in the early steps of glycosami-
noglycan biosynthesis [31,32].
Flow cytometry analysis of the uptake of the S413-PV
peptide by these two cell lines demonstrated that peptide uptake
was more extensive in cells containing heparan sulfate
proteoglycans (CHO-K1; Fig. 3a), when compared to that in
mutant cells lacking proteoglycans (pgs A-745; Fig. 3b).
Nonetheless, the effect of HSPGs on facilitating the cellular
uptake of S413-PV peptide was highly dependent on peptide
concentration: at low peptide concentrations, peptide uptake by
cells lacking proteoglycans (pgs A-745) was approximately 10-
fold lower than that by cells containing proteoglycans (CHO-
K1), whereas, for higher peptide concentrations, smaller
differences were observed (Fig. 3).
Overall, the results from this comparative analysis reinforce
the relevance of HSPGs to the efficient cellular uptake of the
S413-PV peptide, although the presence of these membrane
components at cell surface is not mandatory.
3.4. Interaction of S413-PV peptide with model membranes
To characterize the interaction of the S413-PV peptide with
membranes, a detailed analysis addressing the effect of charge
density of the target membrane and of lipid/peptide ratio on the
fluorescence emission spectra of the S413-PV peptide was
performed.
Interestingly, the emission spectra of the S413-PV peptide
remained unchanged in the presence of neutral vesicles
composed of POPC, whereas upon interaction with negatively
charged vesicles, clear changes in the wavelength of maximal
emission of the S413-PV peptide towards shorter wavelengths
(blue-shift) were observed, concomitantly with significant
increases in fluorescence intensity (Fig. 4).
Partition coefficients (Kp), determined from the changes of
peptide intrinsic fluorescence intensity observed in the presence
of the different lipid vesicles, clearly indicate that the extent of
peptide–membrane interaction is dependent on the surface
density of negatively charged components of the target
membrane (Table 2).
The shift of peptide maximal fluorescence towards shorter
wavelengths (blue-shift) observed in the presence of the
different negatively charged vesicles clearly indicates that,
Fig. 4. Intrinsic fluorescence of the S413-PV peptide in the presence of model
membranes. (a) Effect of target membrane phospholipid composition. Spectra
were acquired in sodium phosphate buffer, pH 7.0, and in the presence of neutral
vesicles composed of POPC or negatively charged vesicles composed of POPC:
POPG (4:1), POPC:POPG (1:1), or POPG, at a lipid/peptide ratio of 6. (b) Effect
of target membrane phospholipid composition and lipid/peptide ratio on the
wavelength of maximal intrinsic fluorescence emission of the S413-PV peptide.
Results obtained at a lipid/peptide ratio of 6 are highlighted. Excitation
wavelength was 280 nm and fluorescence emission was scanned from 300 to
400 nm.
Fig. 3. Uptake of S413-PV peptide by cells genetically deficient in proteoglycan
biosynthesis. Flow cytometry analysis of S413-PV peptide uptake by (a) wild-
type CHO-K1 or (b) pgs A-745 cell lines. Cells were incubated with increasing
concentrations of rhodamine-labeled S413-PV peptide, at 37 °C, for 1 h. Flow
cytometry analysis was performed in live cells, following treatment with trypsin,
to remove non-internalized, surface-bound peptide.
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becomes localized in a highly hydrophobic environment.
Interestingly, the magnitude of the blue-shift of maximal
fluorescence emission of the S413-PV peptide induced by the
negatively charged vesicles increased with the charge density of
target membranes (POPC:POPG (4:1)bPOPC:POPG (1:1)
bPOPG), as well as with lipid/peptide ratio (Fig. 4; Table 2).
As expected, with increasing lipid/peptide ratios, the difference
between the magnitudes of the blue-shifts induced by thedifferent negatively charged vesicles was progressively less
pronounced, the shifts being comparable at lipid/peptide ratios
of 40, or higher (Fig. 4b; Table 2).
In agreement with the lack of interaction between the S413-
PV peptide and neutral membranes, quenching values of
intrinsic fluorescence of the S413-PV peptide by acrylamide in
the presence of lipid vesicles composed of POPC were
comparable to those of the peptide in buffer (as evaluated by
the corresponding KSV; Table 2), indicating that the S413-PV
peptide remains completely exposed to the aqueous environ-
ment in the presence of these vesicles. Conversely, following
interaction of the S413-PV with the different negatively charged
Fig. 5. Circular dichroism analysis of conformational changes of S413-PV
peptide in the presence of model membranes. Circular dichroism spectra of
S413-PV peptide were acquired in sodium phosphate buffer, pH 7.0, or in the
presence of neutral target membranes composed of POPC, or negatively charged
vesicles composed of POPC:POPG (1:1), or POPG, at the indicated lipid/
peptide ratios, as described in Materials and methods.
Table 2
Biophysical characterization of the interaction of S413-PV cell-penetrating
peptide with target membranes of different phospholipid composition
Kp (×10
5) λmax (nm) Δλmax (nm) KSV (M
−1)
S413-PV peptide
buffer, pH 7.0 – 354 – 15.7±0.3
POPC n.d. 354 0 14.8±0.7
POPC:POPG (4:1) 0.23±0.1 328 26 2.3±0.2
POPC:POPG (1:1) 1.17±0.4 326 28 2.1±0.1
POPG 1.96±0.6 324 30 3.1±0.2
Kp values were determined by non-linear regression fitting using Eq. (1); KSV
were determined by fitting Eq. (2) to experimental data; values of λmax, Δλmax
and KSV obtained in the presence of lipid vesicles correspond to a lipid/peptide
ratio of 40.
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cence quenching by acrylamide were observed, regardless of
the density of negatively charged phospholipids in the target
membranes (KSV; Table 2).
Since the Stern–Volmer constants (KSV) in Table 2, are the
product of the bimolecular quenching rate constant times the
fluorescence lifetime, and the quantum yields and lifetimes
increase upon interaction of the peptide with the membranes,
the significant decrease of KSV observed in the presence of
negatively charged membranes are a consequence of the
shielding of the tryptophan to the aqueous environment, and
thereby to the acrylamide quencher.
These results are in agreement with those described to above
regarding the spectral changes of the S413-PV peptide, which
collectively demonstrate that the S413-PV peptide, or at least the
region of the peptide that contains the tryptophan residue,
becomes less exposed to the aqueous environment, most likely
buried into the lipid bilayer, as a consequence of its interaction
with negatively charged membranes.
3.5. S413-PV peptide conformational changes induced by target
membranes
To determine whether the interaction of the S413-PV peptide
with membranes would result in changes of peptide conforma-
tion, circular dichroism experiments were performed in the
presence of lipid vesicles of different compositions (neutral
POPC vesicles, and negatively charged POPC:POPG (1:1) or
POPG vesicles).
Analysis of circular dichroism spectra of the S413-PV
peptide in buffer clearly demonstrated that, when free in
aqueous solution, the peptide is completely unstructured (Fig.
5). Interestingly, the CD spectra of the S413-PV peptide in the
presence of vesicles composed of POPC was virtually
indistinguishable from that obtained in buffer, demonstrating
that no peptide conformational changes are induced by neutral
membranes, even at high lipid/peptide ratios (Fig. 5).
In contrast, prominent changes in the secondary structure of
the S413-PV peptide were observed in the presence of vesicles
containing negatively charged phospholipids (Fig. 5). In
agreement with the changes in the intrinsic fluorescence of the
S413-PV peptide observed previously, the extent of peptide
conformational changes induced by the different vesicles washighly dependent on membrane charge density (compare the
results obtained in the presence of vesicles composed of POPG
or POPC:POPG (1:1) at a lipid/peptide ratio of 4), as well as on
the lipid/peptide ratio (exemplified by the peptide conforma-
tional changes induced by POPC:POPG (1:1) vesicles at lipid/
peptide ratios of 4 and 8). Analysis of the obtained CD spectra
indicates that the changes in peptide conformation induced by
the different negatively charged vesicles are consistent with an
increase in the contribution of an alpha-helical structural
component, and in some cases also of a beta structural
component.
To elucidate whether the S413-PV peptide secondary
structure induced by the negatively charged membranes is a
consequence of specific peptide–membrane interactions, or
rather the outcome of non-specific interactions of electrostatic
nature, and to analyze the relevance of the two components of
the S413-PV fusion peptide to this process, parallel circular
dichroism experiments were performed using the reverse NLS
and scrambled peptides.
Similarly to what was previously observed for the S413-PV
peptide, analysis of the CD spectra of the reverse NLS and
scrambled peptides clearly showed that these peptides are
completely unstructured in aqueous buffer (Fig. 6). Nonethe-
less, the conformational changes of the scrambled peptide,
induced upon its interaction with negatively charged mem-
branes composed of POPG, were significantly less pronounced
than those observed for the S413-PV and reverse NLS peptides,
and no increase of an alpha-helical structural component was
detected (Fig. 6).
Given the similar physico-chemical properties of the S413-
PV, reverse NLS and scrambled peptides (peptide length, mass
Fig. 6. Effect of peptide sequence on the conformational changes induced by
interaction with negatively charged membranes. Circular dichroism spectra of
S413-PV, reverse NLS and scrambled peptides were acquired in sodium
phosphate buffer, pH 7.0, or in the presence of negatively charged vesicles
composed of POPG, at a lipid/peptide ratio of 4, as described in Materials and
methods.
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to form alpha-helical structures, as evaluated by CD
experiments performed in trifluoroethanol (TFE), an apolar,
“membrane-mimicking” solvent (data not shown), the distinct
behavior of the peptides observed in the presence of
negatively charged vesicles clearly demonstrates that the
conformational changes induced by target membranes are
highly dependent on peptide sequence. Moreover, these
findings demonstrate that the sequence derived from the
Dermaseptin S4 peptide, which corresponds to aa 1–13 of the
S413-PV and reverse NLS peptides, is required for the
formation of a helical structure.
4. Discussion
Accumulated reports demonstrating that the cellular uptake
of some cell-penetrating peptides occurs through endocytosis,
or is a consequence of artifacts caused by cell fixation,
prompted the re-evaluation of the mechanism involved in the
cellular uptake of the Dermaseptin-derived S413-PV cell-
penetrating peptide.
In this context, the possible involvement of endocytosis in
the cellular uptake of the S413-PV peptide was investigated by
analyzing the extent of peptide uptake in the presence of drugs
that selectively compromise different endocytic pathways.
Results demonstrating that the uptake of the S413-PV peptide
occurs through a very efficient, non-toxic and dose dependent
mechanism, together with the observations that, among all the
tested drugs, only cytochalasin D had an inhibitory effect on the
cellular uptake of the S413-PV peptide, excluded the involve-
ment of endocytosis as the mechanism responsible for theefficient cellular uptake of the S413-PV peptide. Additional
observations showing that cellular uptake of the S413-PV
peptide was not inhibited upon cell treatment with metabolic
inhibitors that non-specifically block all endocytic pathways
(sodium azide, sodium fluoride, antimycin A; unpublished
observations), as well as the diffuse rather than punctated
intracellular distribution of the peptide, reinforce the lack of
involvement of endocytosis in the cellular uptake of this
peptide.
Although the results from experiments performed at lower
peptide concentrations (0.2 μM and 0.4 μM) demonstrated the
involvement of the clathrin-mediated pathway of endocytosis in
the cellular uptake of the S413-PV peptide [18], it should be
emphasized that at peptide concentrations leading to efficient
uptake of the peptide by the majority of cells (1.0 μM), the
involvement of an endocytosis-independent mechanism of
uptake is clearly prevalent.
The dramatic inhibition of cellular uptake of the S413-PV
peptide by heparin, which mimics GAG moieties of heparan
sulfate proteoglycans ubiquitously present at cell surfaces,
strongly suggests that the interactions between the positively
charged peptide and highly negatively charged membrane
components play an important role in the overall process of
cellular uptake of the peptide.
More interestingly, comparative analysis of peptide uptake
by normal and genetically modified cells that are deficient in
proteoglycan biosynthesis clearly demonstrated that heparan
sulfate proteoglycans potentiate the cellular uptake of the S413-
PV peptide. This effect is particularly relevant for low peptide
concentrations, most likely because binding of the peptide to
cell membranes is not a limiting step to the cellular uptake at
high peptide concentrations. Nonetheless, and in contrast with
previous reports showing that heparan sulfate proteoglycans are
absolutely required for the cellular uptake of full length tat and
tat-fusion proteins [9,10,33], the presence of HSPGs at cell
surface is not mandatory for the cellular uptake of the S413-PV
peptide.
Moreover, the results obtained indicate that binding of the
S413-PV peptide to cell membranes, which is facilitated by
interaction with cell surface HSPGs, can either result in the
endocytic uptake of the peptide (as discussed above for
experiments performed at low S413-PV peptide concentra-
tions), or evoke conformational changes in the peptide,
which occur concomitantly with its insertion into the
membrane leading to its efficient uptake by the majority of
cells.
The data demonstrating that the main mechanism responsible
for the cellular uptake of the S413-PV cell-penetrating peptide is
distinct from endocytosis and is facilitated by the presence of
negatively charged proteoglycans at cell surface indicate that
the membrane translocation of the S413-PV cell-penetrating
peptide results from its direct interaction with biological
membranes. Aiming at gaining insights into the molecular
mechanisms underlying the translocation of the S413-PV
peptide across biological membranes, a detailed characteriza-
tion of the interaction of the S413-PV peptide with model
membranes was performed.
Fig. 7. Helical plot representation of the S413-PV cell-penetrating peptide. Only
the amino acids 1–13, which are derived from the Dermaseptin peptide, are
plotted. Most likely, the sequence corresponding to the NLS of SV40 remains
unstructured due to repulsion forces between positively charged residues.
Hydrophilic amino acids are shown in black.
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peptide uptake, analysis of the interaction of the S413-PV
peptide with target membranes of different phospholipid
compositions clearly demonstrated that the extent of peptide–
membrane interactions is dependent on the relative amount of
negatively charged membrane components on the target
membrane. Although these results indicate that the interactions
established between the S413-PV peptide and target membranes
are essentially of electrostatic nature, the interaction of the
peptide with cell surface proteoglycans may involve some
structural recognition.
As a consequence of the interaction of the S413-PV peptide
with negatively charged target membranes, significant changes
in the intrinsic fluorescence spectra of the peptide were
detected, namely an increase in the fluorescence intensity and
a shift of the wavelength of maximal emission towards shorter
wavelengths (blue-shift). These spectral changes, which are
indicative of an increase in the hydrophobicity of the peptide
environment, were dependent both on the density of negatively
charged phospholipids in the target membrane and on the lipid/
peptide ratio. Remarkably, the magnitude of the blue-shifts
induced upon interaction of the S413-PV peptide with
negatively charged membranes, at the lipid/peptide ratio of 40
(30 nm in the case of POPG vesicles), is extremely high,
specially when compared to those previously reported for other
CPPs, such as the Penetratin, Transportan or Pep-1 peptides, for
which lower shifts were observed [34–37].
In agreement with these changes of peptide intrinsic
fluorescence, the Stern–Volmer quenching constants (KSV)
calculated in the presence of the different negatively charged
vesicles undoubtedly demonstrated that the S413-PV peptide,
or at least the region of the peptide that contains the tryptophan
residue, becomes localized into an extremely hydrophobic
environment as a consequence of its interaction with
negatively charged membranes, most likely inserted into the
lipid bilayer.
Concomitantly with the spectral changes described previ-
ously, circular dichroism analysis revealed that the interaction
of the S413-PV peptide with the negatively charged vesicles
used in this study also induced significant peptide conforma-
tional changes, consistent with an increase in the helical content
of the peptide, whose extent was dependent on the density of
negatively charged phospholipids in the target membrane, as
well as on the lipid/peptide ratio. The similar dependences
observed for the magnitude of the spectral changes and the
extent of peptide conformational changes strongly suggest that
the latter are intricately associated to the insertion of the S413-
PV peptide into target membranes, and presumably to its ability
to translocate across biological membranes.
In this context, it is noteworthy that significant differences
were observed between the conformational changes of the S413-
PV and reverse NLS peptides, induced upon their interaction
with negatively charged target membranes, and those of the
scrambled peptide. This distinct behavior highlights the
importance of the sequence derived from the Dermaseptin S4
peptide to the formation of the alpha-helical structure resulting
from the interaction of the S413-PV peptide with negativelycharged membranes. Moreover, these data strongly indicate that
such conformational changes are of critical importance for the
increased capacity exhibited by the S413-PV peptide to
translocate across biological membranes, as compared to the
scrambled peptide. Interestingly, in contrast to the scrambled
peptide, the amino acids 1–13 of the S413-PV and reverse NLS
peptides, which were originally derived from the Dermaseptin
peptide, have the capacity to be arranged as an amphipathic α-
helix (Fig. 7). Although this feature is not a requirement for
peptide translocation across membranes, the importance of
these structural motifs in inducing local membrane destabiliza-
tion, which can be crucial for peptide translocation, should not
be neglected.
Overall, the results reviewed in the present study demon-
strate that the main mechanism involved in the cellular uptake
of the S413-PV peptide, which is distinct from endocytosis, can
be rationalized in several distinct steps. The process is initiated
by the binding of the S413-PV cell-penetrating peptide to
membranes, as a consequence of electrostatic interactions
established with negatively charged membrane components,
such as the highly negatively charged cell surface heparan
sulfate proteoglycans, in the case of cell membranes. As a
consequence of peptide–membrane interactions that occur upon
binding to target membranes, the S413-PV peptide becomes
inserted into the lipid bilayer, which occurs concomitantly with
significant conformational changes of the peptide that result in
the formation of an amphipathic α-helix. Whether these
conformational changes constitute a requirement for the
insertion of the S413-PV peptide into the lipid bilayer, or a
consequence of this process, is not clear. In any case, the
translocation of the peptide to the intracellular milieu is, most
likely, a consequence of a transient and confined membrane
destabilization induced by the amphipathic α-helix that is
formed upon peptide–membrane interaction. Based on recent
reports demonstrating that the transbilayer membrane potential
that exists across cell membranes (negative inside) is required
345M. Mano et al. / Biochimica et Biophysica Acta 1758 (2006) 336–346for the cellular uptake of several cell-penetrating peptides [38–
40], the possibility that the membrane potential also acts as a
driving force for the membrane translocation of the S413-PV
peptide should not be excluded.
Studies are currently in progress in our laboratory aiming at
evaluating the potential of the S413-PV cell-penetrating
peptide to mediate the intracellular delivery of molecules of
pharmacological interest, including drugs, proteins and nucleic
acids.
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